Clinical Analysis of Bushen Yinao Decoction Combined Levodopa in Treating 40 Patients with Parkinson's Disease

XIE Bing-chuan; SHI Jun; ZHAO Kang; QIU Hui-qin; WANG Ming-wei

doi:10.13422/j.cnki.syfjx.2015110186

您当前的位置：

首页 >

文章列表页 >

Clinical Analysis of Bushen Yinao Decoction Combined Levodopa in Treating 40 Patients with Parkinson's Disease

更新时间：2024-01-04

- Clinical Analysis of Bushen Yinao Decoction Combined Levodopa in Treating 40 Patients with Parkinson's Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 11, Pages: 186-189(2015)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2015110186
  CLC： R742.5
- Published：2015
- 稿件说明：
移动端阅览
XIE Bing-chuan, SHI Jun, ZHAO Kang, et al. Clinical Analysis of Bushen Yinao Decoction Combined Levodopa in Treating 40 Patients with Parkinson's Disease[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(11): 186-189.
DOI：

XIE Bing-chuan, SHI Jun, ZHAO Kang, et al. Clinical Analysis of Bushen Yinao Decoction Combined Levodopa in Treating 40 Patients with Parkinson's Disease[J]. Chinese journal of experimental traditional medical formulae, 2015, 21(11): 186-189. DOI： 10.13422/j.cnki.syfjx.2015110186.

摘要

目的: 观察补肾益脑方联合左旋多巴胺治疗肝肾不足

痰瘀阻络证帕金森病(PD)的临床疗效及对氧化应激和炎症反应的影响. 方法: 将80例PD患者采用随机按数字表法分为对照组和观察组各40例.对照组采用复方卡比多巴片和司来吉兰片治疗

观察组在对照组治疗的基础上加用补肾益脑方内服.两组疗程均为6个月.进行治疗前后帕金森病评定量表(UPDRS)

帕金森病生活质量量表(PDQ-39)

焦虑自评量表(SAS)

抑郁自评量表(SDS)

中医证候评分

检测治疗前后超氧化物歧化酶(SOD)

丙二醛(MDA)

白细胞介素-1 β(IL-1 β)和IL-6水平. 结果: 观察组临床疗效总有效率为87.5%

优于对照组的72.5%(P <0.05);治疗后观察组UPDRSⅠ-Ⅳ评分均低于对照组(P <0.01);治疗后观察组PDQ-39SI

中医证候评分

SAS和SDS均低于对照组(P <0.05

P <0.01);治疗后观察组IL-1 β

IL-6和MDA水平低于对照组

SOD水平高于对照组(P <0.01). 结论: 补肾益脑方联合左旋多巴胺能改善PD(肝肾不足

痰瘀阻络证)运动症状和非运动症状

提高患者生活质量

减轻药物副反应

临床疗效优于单纯西药治疗

其作用机制可能通过减轻氧化应激和炎症反应来实现的.

Abstract

Objective: To observe the curative efficacy of Bushen Yinao decoction combined levodopa in treating Parkinson's disease (PD)

and to investigate its influence on oxidative stress and inflammatory response. Method: Eighty patients with PD were randomly divided into the control group (40 cases) and the observation group (40 cases) by a random number table. Patients in the control group received compound carbidopa tablets and selegiline tablets. Based on the treatment of the control group

patients in the observation group added Bushen Yinao decoction. All patients in both two groups received 6 months of treatment. Before and after treatment

scores of unified PD rating scale (UPDRS)

PD quality of life scale (PDQ-39)

self-rating anxiety scale (SAS)

self-rating depression scale (SDS)

traditional Chinese medical (TCM) syndrome scores were graded. Levels of superoxide dismutase (SOD)

malondialdehyde (MDA)

interleukin-1 β (IL-1 β) and interleukin-6 (IL-6) were detected. Result: The total clinical curative rate of in the observation group was 87.5%

which was superior to that of 72.5% in the control group (P <0.05). After treatment

UPDRS Ⅰ-Ⅳ score in the observation group was less than that in the control group (P <0.01). Levels of PDQ-39SI

TCM syndrome score

SAS and SDS in the observation group were inferior to those in the control group (P <0.05

P <0.01). Standards of IL-1 β

IL-6 and MDA in the observation group were lower than those in the control group

while the SOD level was higher than that in the control group (P <0.01). Conclusion: Bushen Yinao decoction combined levodopa could improve motor and non-motor symptoms

enhance patients' quality of life

reduce the side effects of levodopa in treating PD. Its clinical curative effect is superior to using western medicine treatment alone. The mechanism may be related to reducing oxidative stress and inflammation.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Bushen Huoxue Decoction to Blood Pressure Variability and Quality of Life of Patients with Kidney Deficiency and Blood Stasis-type Hypertension

Yijingtang Reduces Ovarian Inflammatory Responses in Rat Model of Diminished Ovarian Reserve via TLR4/MyD88/NF-κB Signaling Pathway

Correlation Between Quality of Life and Traditional Chinese Medicine Syndromes in Patients with Myasthenia Gravis

Mechanism of Shengmai Injection Against Cerebral Ischemia Based on Proteomics

DIA Proteomics Reveals Mechanism of Acanthopanacis Senticosi Radix et Rhizoma seu Caulis Extract in Treating α-Syn Transgenic Parkinson's Disease in Mice

Related Author

TENG Ying-hua

XIE Rui

SHI Xian-zhi

HU Heng

CHU Jijun

LI Zhe

CHU Haijing

YU Jing

Related Institution

The First Clinical Medical School of Anhui University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

The Affiliated Hospital of Changchun University of Chinese Medicine

The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine

Changchun University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰